Vanguard Asset Management
EWTX icon

Vanguard Asset Management’s Edgewise Therapeutics EWTX Stock Holding History

Vanguard Asset Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.45M Hold
35,744
– – ﹤0.01% 1709
2026
Q1 		$1.13M Buy
+35,744
New +$1.03M ﹤0.01% 1736

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Asset Management's EWTX Position: Q2 2026 in Review

Vanguard Asset Management held its Edgewise Therapeutics (EWTX) position steady in Q2 2026 at 35,744 shares worth $1.45M. The position accounts for ﹤0.01% of the portfolio, ranked #1709.

Vanguard Asset Management first reported a position in EWTX in Q1 2026 and has held it in 2 quarters since. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Vanguard Asset Management held 35,744 shares of Edgewise Therapeutics worth $1.45M as of Q2 2026.
  • Vanguard Asset Management left its Edgewise Therapeutics share count unchanged in Q2 2026.
  • Edgewise Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1709 holding.
  • Vanguard Asset Management first reported a position in Edgewise Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.